Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Axsome Thera (NQ: AXSM ) 76.05 +2.42 (+3.29%) Streaming Delayed Price Updated: 3:48 PM EDT, Jun 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Axsome Thera < Previous 1 2 3 4 5 Next > Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories June 05, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month June 04, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month June 03, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Participate in Upcoming Investor Conferences May 30, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024 May 29, 2024 Data on solriamfetol featured in two oral plenary sessions From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting May 28, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 06, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Recognizes May as Mental Health Awareness Month May 01, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 30, 2024 From Bragar Eagel & Squire Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting April 15, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 12, 2024 From Bragar Eagel & Squire Via GlobeNewswire Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 April 10, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm April 03, 2024 From Bragar Eagel & Squire Via GlobeNewswire Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder April 01, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm March 25, 2024 From Bragar Eagel & Squire Via GlobeNewswire Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients March 25, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy March 25, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder March 19, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference March 05, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 20, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire 5 medical stocks growing earnings by triple digits February 06, 2024 There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning Via MarketBeat Topics Economy Exposures Economy Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20 January 23, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones January 04, 2024 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting December 11, 2023 From Axsome Therapeutics, Inc. Via GlobeNewswire Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today December 07, 2023 From Axsome Therapeutics, Inc. Via GlobeNewswire AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM November 27, 2023 From The Rosen Law Firm PA Via GlobeNewswire AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM November 25, 2023 WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)... Via NewMediaWire Topics Lawsuit Exposures Financial Legal < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
